Clinical Characteristics.

†<p>Group A (LVEDP <16 mmHg) versus Group C (LVEDP> 30 mmHg), <i>p</i><0.05 in <i>post hoc</i> analysis.</p>‡<p>Group B (LVEDP 16–30 mmHg) versus Group C, <i>p</i><0.05 in <i>post hoc</i> analysis.</p><p>ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BP, blood pressure; LVEDP, left ventricular end-diastolic pressure; NYHA, New York Heart Association.</p><p>Clinical Characteristics.</p

The flow chart of patient selection process.

<p>The flow chart of patient selection process.</p

Conventional Two-dimensional and Doppler Echocardiographic Findings.

†<p>Group A versus Group C, p<0.05 in post hoc analysis.</p>‡<p>Group B versus Group C, p<0.05 in post hoc analysis.</p><p>A, late diastolic transmitral Doppler flow velocity; a′, late mitral annular diastolic velocity; DT, deceleration time; E, early diastolic transmitral Doppler flow velocity; eas, ratio e′/(a′ X s′); EDV, end diastolic volume; EF, ejection fraction; ESV, end systolic volume; e′, early mitral annular diastolic velocity; IVRT, isovolumic relaxation time; LA, left atrium; LV, left ventricular; MPI, myocardial performance index; s′, mitral annular systolic velocity.</p><p>Conventional Two-dimensional and Doppler Echocardiographic Findings.</p

Concentrations of N-terminal propeptide of type III procollagen in three groups of patients with acute coronary syndrome.

<p>Concentrations of N-terminal propeptide of type III procollagen in three groups of patients with acute coronary syndrome.</p

Cardiac events-free survival curves categorized by whether PIIINP level is higher (upper curve) or less (lower curve) than 5.09 (median value).

<p>Number of patients at risk during follow-up is indicated below the x axis.</p

Lesion Length Impacts Long Term Outcomes of Drug-Eluting Stents and Bare Metal Stents Differently

<div><h3>Background</h3><p>Long lesions have been associated with adverse outcomes in percutaneous coronary interventions with bare metal stents (BMS). However, the exact impact of lesion length on the short- and long-term outcomes of drug-eluting stent (DES) implantations is not as clear.</p> <h3>Methods and Results</h3><p>This study compared the impact of lesion length on angiographic and clinical outcomes of BMS and DES in a single-center prospective registry. Lesion length was divided into tertiles. The primary endpoints were angiographically defined binary in-stent restenosis (ISR) rate and major adverse cardiac event (MACE). Of the 4,312 de novo lesions in 3,447 consecutive patients in the CAPTAIN registry, 2,791 lesions (of 2,246 patients) received BMS, and the remaining 1,521 lesions (of 1,201 patients) received DES. The mean follow-up duration was 4.5 years. The longer the lesion, the higher the ISR rate (14%, 18%, and 29%, p<0.001) and the lower the MACE-free survivals (p = 0.007) in the BMS group. However, lesion length showed no such correlation with ISR rates (4.7%, 3.3%, and 7.8%, p = 0.67) or MACE-free survivals (p = 0.19) in the DES group.</p> <h3>Conclusions</h3><p>In our single-center prospective registry, lesion length defined in tertiles has no impact on the short-term (ISR) or long-term (MACE) outcomes of patients implanted with DES. In contrast, longer lesion correlates with higher ISR and MACE rates in BMS group.</p> </div

Intra-stent restenosis rate defined by scheduled angiographic follow-up of various lesion length.

<p>BMS: bare metal stent. DES: drug-eluting stents.</p

Kaplan-Meier estimates: major adverse cardiac events (MACE) free survival of patients with various lesion length.

<p>BMS: bare metal stent. DES: drug-eluting stents.</p

Lesions and Procedural Characteristics.

<p>BMS, bare metal stent; DES, drug-eluting stent; LAD, left anterior descending; LCX, left circumflex; RCA, right coronary artery.</p

Patient Characteristics.

<p>CAD: coronary artery disease; LVEF: left ventricular ejection fraction; PTCA: percutaneous transluminal coronary angioplasty.</p